Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590161 · ClinicalTrials.gov registry record · Phase 2
Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
A Phase 2 study, sponsored by Case Western Reserve University.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
NCT00590161 is a Phase 2 study that has completed, run by Case Western Reserve University. The registered enrollment target is 55 participants.
The verdict
NCT00590161, a Phase 2 study, has completed, sponsored by Case Western Reserve University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
Study Summary
One third of the population in the United States has nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis.Currently, there is no proven therapy for patients with NASH. The investigators core hypothesis is that therapy of patients with NASH with pentoxifylline (PTX) for one year will result in improvement of biochemical parameters of liver disease and hepatic histology. The focus of this proposal is on the effectiveness of pentoxifylline (PTX) in improving laboratory and tissue parameters of liver disease, parameters of insulin-resistance, and levels of cytokines in patients with NASH.
Interventions
- DRUG placebo
- DRUG pentoxifylline (PTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590161
The ClinicalTrials.gov registry entry for NCT00590161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Western Reserve University, which has 141 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00590161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590161 about?
NCT00590161 is a clinical study titled "Pentoxifylline in Patients With Nonalcoholic Steatohepatitis". One third of the population in the United States has nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis.Currently, there is no proven therapy for patients with NASH. The investigators core hypothesis is that therapy of ...
What is the current status of trial NCT00590161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2006-12. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00590161?
The interventions under investigation include: placebo (DRUG), pentoxifylline (PTX) (DRUG).
Who is sponsoring clinical trial NCT00590161?
This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.